The firm says recent Camp Lejeune litigation developments include a court order requiring Track 1 plaintiffs to prove exposure and general causation before trial. It also says the court selected five diseases for Track 2 discovery, including prostate cancer, kidney disease, lung cancer, liver cancer and breast cancer..